Background: Rheumatoid arthritis (RA) is associated with high frequency of comorbidities and increased risk of polypharmacy. Although there is a great potential for complications, there is a gap in literature on polypharmacy in patients with rheumatic arthritis.
Objective: To evaluate the prevalence and factors associated with polypharmacy in a population in a real-life setting.